Study of Pregabalin Treatment and Rehabilitation for Chronic Fatigue in Post-COVID Syndrome Patients

2 1 1

What is this study about?

This study focuses on treating chronic fatigue syndrome that develops after COVID-19 infection, also known as post-COVID syndrome. The study will evaluate the effectiveness of two different treatment approaches: medication with pregabalin tablets and complex rehabilitation. Pregabalin is a prescription medication that will be compared to a placebo during the research.

The purpose of this study is to determine how well pregabalin and complex rehabilitation help reduce fatigue symptoms in people who have experienced persistent tiredness for at least 6 months after having COVID-19. The study will measure changes in fatigue levels and physical abilities, including how far participants can walk.

During the study, participants will take either pregabalin tablets or placebo tablets. The maximum daily dose of pregabalin will be 300 mg. The study will last for 6 months, during which various aspects of participants’ health will be monitored, including their energy levels, walking ability, quality of life, sleep patterns, and emotional well-being. Regular assessments will be conducted to track participants’ progress throughout the study period.

1 Initial assessment

Your participation begins with an assessment to confirm chronic fatigue syndrome related to previous COVID-19 infection

The medical team will verify that at least 6 months have passed since your documented SARS-CoV-2 infection

Female participants will undergo a pregnancy test and must confirm using effective contraception throughout the study

2 Baseline measurements

You will complete several questionnaires about your fatigue levels, life satisfaction, and mental health

Physical tests will be conducted, including a 6-minute walking test to measure your walking distance

Various cognitive tests will be performed to assess your mental function

Blood samples will be collected to analyze inflammatory markers

3 Treatment period start

You will receive either pregabalin tablets (75 mg) or placebo tablets for oral use

The medication or placebo must be taken as prescribed throughout the study period

4 3-month assessment

After 3 months, you will undergo the same tests and questionnaires as at the beginning

Your walking ability, fatigue levels, and other symptoms will be reassessed

The medical team will check for any side effects or health changes

5 6-month assessment

Final round of tests and questionnaires will be conducted

Physical and cognitive assessments will be repeated

Blood samples will be taken for final analysis

The medical team will perform a final safety evaluation

Who Can Join the Study?

Patient must provide written informed consent showing they understand and agree to participate in the study
Age requirement: Must be between 18 and 65 years old when signing the consent form
Must have documented evidence of previous SARS-CoV-2 infection (COVID-19) from at least 6 months ago, proven by either:
– A positive PCR test result
– A positive antigen test result
– A recovery certificate
– Medical records confirming infection
– Documentation of asymptomatic infection
Must meet the criteria for chronic fatigue syndrome according to National Academy of Medicine (2015) standards during screening
For women participants:
– Must either be unable to have children (post-menopausal or permanently sterilized), OR
– If able to have children, must have a negative pregnancy test during screening and use effective contraception during the study and for 7 days after last treatment
Must agree to participate in all study activities
Must be capable of understanding provided information and giving informed consent before screening begins

Who Cannot Join the Study?

Age below 18 years or above 65 years
Pregnant or breastfeeding women
History of allergic reactions to pregabalin or similar medications
Severe kidney disease or impaired kidney function
Active liver disease or significantly elevated liver enzymes
Uncontrolled diabetes
History of substance abuse or addiction
Severe psychiatric disorders requiring medication
Current participation in other clinical trials
Unable to provide informed consent
Severe cardiovascular disease (heart problems)
History of seizures or epilepsy
Taking medications that may interact with pregabalin
Inability to complete the rehabilitation program
Severe respiratory problems that prevent exercise
Unstable medical conditions that could interfere with the study
Chronic pain conditions unrelated to post-COVID syndrome
Major surgery planned during the study period
Regular use of medications that affect fatigue symptoms
Inability to attend regular follow-up visits

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Nutcrykr Ipjmfgtn Gbdjuntzf Rhfiwnkkqivu I Ronesxxmofjaz Iw Pjiyh Df Htfl Maqv Enzparmt Rcjjzhp	Warsaw	Poland

Trial status

Country	Status	Recruitment Start
Poland	Not recruiting	01.03.2023

Trial locations

Investigated drugs:

Pregabalin

Pregabalin is a medication commonly used to treat nerve pain and anxiety disorders. In this trial, it is being studied for its potential to help patients who experience chronic fatigue after COVID-19 infection. It works by reducing abnormal electrical signals in the nervous system and may help improve energy levels and reduce fatigue symptoms.

Complex rehabilitation is a comprehensive treatment approach that includes various physical exercises, therapeutic techniques, and lifestyle modifications. This therapy program is designed to help patients recover their strength, endurance, and daily functioning abilities after experiencing post-COVID syndrome. It typically involves supervised activities and exercises tailored to each patient’s specific needs and capabilities.

Investigated diseases:

Chronic Fatigue Syndrome (CFS) associated with Post-COVID Syndrome – A complex condition that develops after COVID-19 infection, characterized by severe fatigue that doesn’t improve with rest. Patients experience persistent exhaustion that significantly affects daily activities and can last for months. The condition often includes other symptoms such as muscle weakness, difficulty with concentration and memory, sleep problems, and reduced physical endurance. The fatigue typically worsens with physical or mental activity. The condition can fluctuate in intensity over time, with periods of increased and decreased severity.

Trial ID:

2024-516174-30-01

Protocol code:

NIGRIR_001POSTCOVID

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of Pregabalin Treatment and Rehabilitation for Chronic Fatigue in Post-COVID Syndrome Patients

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?